05.28.08
Juvaris BioTherapeutics Initiates Phase I Clinical Trial of JVRS-100 Adjuvanted Seasonal Influenza Vaccine »more

03.13.08
Juvaris BioTherapeutics Announces the Appointment of Grant E. Pickering as Chief Executive Officer »more
03.04.08
Bayer HealthCare and Juvaris BioTherapeutics announce major licensing agreement »more
01.22.08
Carol L. Brosgart, M.D., Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc. »more
01.15.08
Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention »more
09.26.07
Juvaris BioTherapeutics Announces Six Scientific Presentations at the Infectious Diseases Society of America (IDSA) meeting. »more
Juvaris news archive
Welcome to Juvaris BioTherapeutics
Juvaris BioTherapeutics, located in Pleasanton, California, is developing therapeutic vaccines for cancer and infectious diseases using its novel technology platform of cationic lipids and non-coding DNA complexes. These complexes are capable of up-regulating the immune response, in particular cell-mediated immunity, at least 20-fold greater than existing technologies. The company has completed pre-clinical studies in many species including rodents and dogs, established manufacturing processes, and secured contract suppliers; positioning the company to initiate toxicology studies leading to clinical trials.